{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T14:03:48Z","timestamp":1780581828974,"version":"3.54.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,6,3]],"date-time":"2023-06-03T00:00:00Z","timestamp":1685750400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,3]],"date-time":"2023-06-03T00:00:00Z","timestamp":1685750400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The diagnosis of probable cerebral amyloid angiopathy (CAA) is currently mostly based on characteristics of brain MRI. Blood biomarkers would be a cost-effective, easily accessible diagnostic method that may complement diagnosis by MRI and aid in monitoring disease progression. We studied the diagnostic potential of plasma A\u03b238, A\u03b240, and A\u03b242 in patients with hereditary Dutch-type CAA (D-CAA) and sporadic CAA (sCAA).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>All A\u03b2 peptides were quantified in the plasma by immunoassays in a discovery cohort (11 patients with presymptomatic D-CAA and 24 patients with symptomatic D-CAA, and 16 and 24 matched controls, respectively) and an independent validation cohort (54 patients with D-CAA, 26 presymptomatic and 28 symptomatic, and 39 and 46 matched controls, respectively). In addition, peptides were quantified in the plasma in a group of 61 patients with sCAA and 42 matched controls. We compared A\u03b2 peptide levels between patients and controls using linear regression adjusting for age and sex.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In the discovery cohort, we found significantly decreased levels of all A\u03b2 peptides in patients with presymptomatic D-CAA (A\u03b238: <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001; A\u03b240: <jats:italic>p<\/jats:italic>\u2009=\u20090.009; A\u03b242: <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) and patients with symptomatic D-CAA (A\u03b238: <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001; A\u03b240: <jats:italic>p<\/jats:italic>\u2009=\u20090.01; A\u03b242: <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) compared with controls. In contrast, in the validation cohort, plasma A\u03b238, A\u03b240, and A\u03b242 were similar in patients with presymptomatic D-CAA and controls (A\u03b238: <jats:italic>p<\/jats:italic>\u2009=\u20090.18; A\u03b240: <jats:italic>p<\/jats:italic>\u2009=\u20090.28; A\u03b242: <jats:italic>p<\/jats:italic>\u2009=\u20090.63). In patients with symptomatic D-CAA and controls, plasma A\u03b238 and A\u03b240 were similar (A\u03b238: <jats:italic>p<\/jats:italic>\u2009=\u20090.14; A\u03b240: <jats:italic>p<\/jats:italic>\u2009=\u20090.38), whereas plasma A\u03b242 was significantly decreased in patients with symptomatic D-CAA (<jats:italic>p<\/jats:italic>\u2009=\u20090.033). Plasma A\u03b238, A\u03b240, and A\u03b242 levels were similar in patients with sCAA and controls (A\u03b238: <jats:italic>p<\/jats:italic>\u2009=\u20090.092; A\u03b240: <jats:italic>p<\/jats:italic>\u2009=\u20090.64. A\u03b242: <jats:italic>p<\/jats:italic>\u2009=\u20090.68).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Plasma A\u03b242 levels, but not plasma A\u03b238 and A\u03b240, may be used as a biomarker for patients with symptomatic D-CAA. In contrast, plasma A\u03b238, A\u03b240, and A\u03b242 levels do not appear to be applicable as a biomarker in patients with sCAA.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13195-023-01245-2","type":"journal-article","created":{"date-parts":[[2023,6,3]],"date-time":"2023-06-03T08:02:19Z","timestamp":1685779339000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Plasma amyloid beta 42 is a biomarker for patients with hereditary, but not sporadic, cerebral amyloid angiopathy"],"prefix":"10.1186","volume":"15","author":[{"given":"Anna M.","family":"de Kort","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Bea","family":"Kuiperij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lieke","family":"J\u00e4kel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris","family":"Kersten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingeborg","family":"Rasing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellis S.","family":"van Etten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanneke","family":"van Rooden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias J. P.","family":"van Osch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marieke J. H.","family":"Wermer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gisela M.","family":"Terwindt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Floris H. B. M.","family":"Schreuder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catharina J. M.","family":"Klijn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel M.","family":"Verbeek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,3]]},"reference":[{"issue":"1","key":"1245_CR1","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1002\/alz.12366","volume":"181","author":"L J\u00e4kel","year":"2022","unstructured":"J\u00e4kel L, De Kort AM, Klijn CJ, Schreuder FH, Verbeek MM. Prevalence of cerebral amyloid angiopathy: A systematic review and meta-analysis. Alzheimers Dement. 2022;181(1):10\u201328.","journal-title":"Alzheimers Dement."},{"issue":"3","key":"1245_CR2","first-page":"518","volume":"49","author":"E Bakker","year":"1991","unstructured":"Bakker E, van Broeckhoven C, Haan J, Voorhoeve E, van Hul W, Levy E, et al. DNA diagnosis for hereditary cerebral hemorrhage with amyloidosis (Dutch type). Am J Hum Genet. 1991;49(3):518\u201321.","journal-title":"Am J Hum Genet"},{"key":"1245_CR3","first-page":"100","volume":"3","author":"A Biffi","year":"2022","unstructured":"Biffi A. Main features of hereditary cerebral amyloid angiopathies: a systematic review. Cereb Circ Cogn Behav. 2022;3:100\u201324.","journal-title":"Cereb Circ Cogn Behav."},{"issue":"8","key":"1245_CR4","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/S1474-4422(22)00208-3","volume":"21","author":"A Charidimou","year":"2022","unstructured":"Charidimou A, Boulouis G, Frosch MP, Baron J-C, Pasi M, Albucher JF, et al. The Boston criteria version 2.0 for cerebral amyloid angiopathy: a multicentre, retrospective, MRI-neuropathology diagnostic accuracy study. Lancet Neurol. 2022;21(8):714\u201325.","journal-title":"Lancet Neurol"},{"issue":"2","key":"1245_CR5","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1002\/ana.21694","volume":"66","author":"MM Verbeek","year":"2009","unstructured":"Verbeek MM, Kremer BPH, Rikkert MO, Van Domburg PHMF, Skehan ME, Greenberg SM. Cerebrospinal fluid amyloid \u03b240 is decreased in cerebral amyloid angiopathy. Ann Neurol. 2009;66(2):245\u20139.","journal-title":"Ann Neurol"},{"issue":"2","key":"1245_CR6","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1212\/WNL.0000000000003486","volume":"88","author":"ES van Etten","year":"2017","unstructured":"van Etten ES, Verbeek MM, van der Grond J, Zielman R, van Rooden S, van Zwet EW, et al. \u03b2-Amyloid in CSF: biomarker for preclinical cerebral amyloid angiopathy. Neurology. 2017;88(2):169\u201376.","journal-title":"Neurology"},{"key":"1245_CR7","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1002\/ana.26610","volume":"93","author":"AM De Kort","year":"2023","unstructured":"De Kort AM, Kuiperij HB, Marques TM, J\u00e4kel L, van den Berg E, Kersten I, et al. Decreased cerebrospinal fluid A\u03b2 38, 40, 42, and 43 levels in sporadic and hereditary cerebral amyloid angiopathy. Ann Neurol. 2023;93:1173\u201386.","journal-title":"Ann Neurol."},{"key":"1245_CR8","doi-asserted-by":"publisher","first-page":"977","DOI":"10.3233\/JAD-170458","volume":"60","author":"S Hilal","year":"2017","unstructured":"Hilal S, Akoudad S, van Duijn CM, Niessen WJ, Verbeek MM, Vanderstichele H, et al. Plasma amyloid-\u03b2 levels, cerebral small vessel disease, and cognition: the Rotterdam study. J Alzheimer\u2019s Dis. 2017;60:977\u201387.","journal-title":"J Alzheimer\u2019s Dis"},{"issue":"4","key":"1245_CR9","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1161\/STROKEAHA.117.019810","volume":"49","author":"EMC van Leijsen","year":"2018","unstructured":"van Leijsen EMC, Kuiperij HB, Kersten I, Bergkamp MI, van Uden IWM, Vanderstichele H, et al. Plasma A\u03b2 (amyloid-\u03b2) levels and severity and progression of small vessel disease. Stroke. 2018;49(4):884\u201390.","journal-title":"Stroke"},{"issue":"6","key":"1245_CR10","doi-asserted-by":"publisher","first-page":"2931","DOI":"10.3390\/ijms22062931","volume":"22","author":"P Chatterjee","year":"2021","unstructured":"Chatterjee P, Tegg M, Pedrini S, Fagan AM, Xiong C, Singh AK, et al. Plasma amyloid-beta levels in a pre-symptomatic dutch-type hereditary cerebral amyloid angiopathy pedigree: a cross-sectional and longitudinal investigation. Int J Mol Sci. 2021;22(6):2931.","journal-title":"Int J Mol Sci"},{"issue":"12","key":"1245_CR11","doi-asserted-by":"publisher","first-page":"3041","DOI":"10.1161\/STROKEAHA.116.014418","volume":"47","author":"S van Rooden","year":"2016","unstructured":"van Rooden S, van Opstal AM, Labadie G, Terwindt GM, Wermer MJ, Webb AG, et al. Early magnetic resonance imaging and cognitive markers of hereditary cerebral amyloid angiopathy. Stroke. 2016;47(12):3041\u20134.","journal-title":"Stroke"},{"key":"1245_CR12","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1161\/STROKEAHA.121.035019","volume":"53","author":"EA Koemans","year":"2021","unstructured":"Koemans EA, Voigt S, Rasing I, van Harten TW, Jolink WM, Schreuder FH, et al. Cerebellar superficial siderosis in cerebral amyloid angiopathy. Stroke. 2021;53:552\u20137.","journal-title":"Stroke."},{"issue":"17","key":"1245_CR13","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1212\/WNL.0b013e3181dad605","volume":"74","author":"J Linn","year":"2010","unstructured":"Linn J, Halpin A, Demaerel P, Ruhland J, Giese AD, Dichgans M, et al. Prevalence of superficial siderosis in patients with cerebral amyloid angiopathy. Neurology. 2010;74(17):1346\u201350.","journal-title":"Neurology"},{"key":"1245_CR14","doi-asserted-by":"publisher","first-page":"118175","DOI":"10.1016\/j.neuroimage.2021.118175","volume":"237","author":"K Eckstein","year":"2021","unstructured":"Eckstein K, Bachrata B, Hangel G, Widhalm G, Enzinger C, Barth M, et al. Improved susceptibility weighted imaging at ultra-high field using bipolar multi-echo acquisition and optimized image processing: CLEAR-SWI. Neuroimage. 2021;237:118175.","journal-title":"Neuroimage"},{"issue":"8","key":"1245_CR15","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1001\/jamaneurol.2016.0832","volume":"73","author":"A Charidimou","year":"2016","unstructured":"Charidimou A, Martinez-Ramirez S, Reijmer YD, Oliveira-Filho J, Lauer A, Roongpiboonsopit D, et al. Total magnetic resonance imaging burden of small vessel disease in cerebral amyloid angiopathy: an imaging-pathologic study of concept validation. JAMA Neurol. 2016;73(8):994\u20131001.","journal-title":"JAMA Neurol"},{"issue":"3","key":"1245_CR16","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.nbd.2003.08.019","volume":"14","author":"M Bornebroek","year":"2003","unstructured":"Bornebroek M, De Jonghe C, Haan J, Kumar-Singh S, Younkin S, Roos R, et al. Hereditary cerebral hemorrhage with amyloidosis Dutch type (AbetaPP 693): decreased plasma amyloid-beta 42 concentration. Neurobiol Dis. 2003;14(3):619\u201323.","journal-title":"Neurobiol Dis"},{"issue":"1","key":"1245_CR17","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1111\/j.1749-6632.2000.tb06361.x","volume":"903","author":"SMCH Greenberg","year":"2000","unstructured":"Greenberg SMCH, O\u2019Donnell HC, Rosand J, Segal AZ, Younkin LH, Younkin SG, Rebeck GW. Plasma \u03b2-amyloid peptide, transforming growth factor-\u03b21, and risk for cerebral amyloid angiopathy. Ann N Y Acad Sci. 2000;903(1):144\u20139.","journal-title":"Ann N Y Acad Sci"},{"issue":"1\u20134","key":"1245_CR18","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1159\/000333811","volume":"10","author":"M Hernandez-Guillamon","year":"2012","unstructured":"Hernandez-Guillamon M, Delgado P, Penalba A, Rodriguez-Luna D, Molina CA, Rovira A, et al. Plasma \u03b2-amyloid levels in cerebral amyloid angiopathy-associated hemorrhagic stroke. Neurodegener Dis. 2012;10(1\u20134):320\u20133.","journal-title":"Neurodegener Dis"},{"issue":"4","key":"1245_CR19","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1111\/j.1440-1789.2005.00631.x","volume":"25","author":"M Maat-Schieman","year":"2005","unstructured":"Maat-Schieman M, Roos R, Van Duinen S. Hereditary cerebral hemorrhage with amyloidosis-Dutch type. Neuropathology. 2005;25(4):288\u201397.","journal-title":"Neuropathology"},{"issue":"1","key":"1245_CR20","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41582-019-0281-2","volume":"16","author":"SM Greenberg","year":"2020","unstructured":"Greenberg SM, Bacskai BJ, Hernandez-Guillamon M, Pruzin J, Sperling R, van Veluw SJ. Cerebral amyloid angiopathy and Alzheimer disease\u2014one peptide, two pathways. Nat Rev Neurol. 2020;16(1):30\u201342.","journal-title":"Nat Rev Neurol"},{"issue":"3","key":"1245_CR21","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/S0197-4580(01)00317-7","volume":"23","author":"OR Monro","year":"2002","unstructured":"Monro OR, Mackic JB, Yamada S, Segal MB, Ghiso J, Maurer C, et al. Substitution at codon 22 reduces clearance of Alzheimer\u2019s amyloid-beta peptide from the cerebrospinal fluid and prevents its transport from the central nervous system into blood. Neurobiol Aging. 2002;23(3):405\u201312.","journal-title":"Neurobiol Aging"},{"issue":"4","key":"1245_CR22","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s00401-011-0861-8","volume":"122","author":"JB Toledo","year":"2011","unstructured":"Toledo JB, Vanderstichele H, Figurski M, Aisen PS, Petersen RC, Weiner MW, et al. Factors affecting A\u03b2 plasma levels and their utility as biomarkers in ADNI. Acta Neuropathol. 2011;122(4):401\u201313.","journal-title":"Acta Neuropathol"},{"issue":"8","key":"1245_CR23","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1016\/j.neuint.2009.08.006","volume":"55","author":"N Le Bastard","year":"2009","unstructured":"Le Bastard N, Aerts L, Leurs J, Blomme W, De Deyn PP, Engelborghs S. No correlation between time-linked plasma and CSF A\u03b2 levels. Neurochem Int. 2009;55(8):820\u20135.","journal-title":"Neurochem Int"},{"issue":"3","key":"1245_CR24","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.neurobiolaging.2008.03.027","volume":"31","author":"O Hansson","year":"2010","unstructured":"Hansson O, Zetterberg H, Vanmechelen E, Vanderstichele H, Andreasson U, Londos E, et al. Evaluation of plasma Abeta(40) and Abeta(42) as predictors of conversion to Alzheimer\u2019s disease in patients with mild cognitive impairment. Neurobiol Aging. 2010;31(3):357\u201367.","journal-title":"Neurobiol Aging"},{"key":"1245_CR25","doi-asserted-by":"publisher","first-page":"26801","DOI":"10.1038\/srep26801","volume":"6","author":"S Janelidze","year":"2016","unstructured":"Janelidze S, Stomrud E, Palmqvist S, Zetterberg H, van Westen D, Jeromin A, et al. Plasma \u03b2-amyloid in Alzheimer\u2019s disease and vascular disease. Sci Rep. 2016;6:26801.","journal-title":"Sci Rep"},{"issue":"11","key":"1245_CR26","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1001\/jamaneurol.2021.3180","volume":"78","author":"S Janelidze","year":"2021","unstructured":"Janelidze S, Teunissen CE, Zetterberg H, Allu\u00e9 JA, Sarasa L, Eichenlaub U, et al. Head-to-head comparison of 8 plasma amyloid-\u03b2 42\/40 assays in Alzheimer disease. JAMA Neurol. 2021;78(11):1375\u201382.","journal-title":"JAMA Neurol"},{"issue":"12","key":"1245_CR27","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1001\/archneurol.2012.18107","volume":"69","author":"Y Huang","year":"2012","unstructured":"Huang Y, Potter R, Sigurdson W, Kasten T, Connors R, Morris JC, et al. \u03b2-Amyloid dynamics in human plasma. Arch Neurol. 2012;69(12):1591\u20137.","journal-title":"Arch Neurol"},{"key":"1245_CR28","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.3233\/JAD-170784","volume":"62","author":"CE Teunissen","year":"2018","unstructured":"Teunissen CE, Chiu M-J, Yang C-C, Yang S-Y, Scheltens P, Zetterberg H, et al. Plasma amyloid-\u03b2 (A\u03b2 42) correlates with cerebrospinal fluid A\u03b2 42 in Alzheimer\u2019s disease. J Alzheimer\u2019s Dis. 2018;62:1857\u201363.","journal-title":"J Alzheimer\u2019s Dis"},{"key":"1245_CR29","unstructured":"Alzheimer\u2019s disease vs control: A\u03b242 (plasma and serum), http:\/\/www.alzforum.org\/alzbiomarker\/meta-analysis\/alzheimers-disease-vs-control-av42-plasma-and-serum, Version 3.0, July 2021."},{"issue":"15","key":"1245_CR30","doi-asserted-by":"publisher","first-page":"e1580","DOI":"10.1212\/WNL.0000000000009240","volume":"94","author":"JD Doecke","year":"2020","unstructured":"Doecke JD, P\u00e9rez-Grijalba V, Fandos N, Fowler C, Villemagne VL, Masters CL, et al. Total A\u03b242\/A\u03b240 ratio in plasma predicts amyloid-PET status, independent of clinical AD diagnosis. Neurology. 2020;94(15):e1580\u201391.","journal-title":"Neurology"},{"issue":"1","key":"1245_CR31","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s13195-019-0549-1","volume":"11","author":"V P\u00e9rez-Grijalba","year":"2019","unstructured":"P\u00e9rez-Grijalba V, Arbizu J, Romero J, Prieto E, Pesini P, Sarasa L, et al. Plasma A\u03b242\/40 ratio alone or combined with FDG-PET can accurately predict amyloid-PET positivity: a cross-sectional analysis from the AB255 study. Alzheimers Res Ther. 2019;11(1):96.","journal-title":"Alzheimers Res Ther"},{"issue":"10","key":"1245_CR32","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1038\/nrneurol.2017.111","volume":"13","author":"J Wang","year":"2017","unstructured":"Wang J, Gu BJ, Masters CL, Wang Y-J. A systemic view of Alzheimer disease\u2014insights from amyloid-\u03b2 metabolism beyond the brain. Nat Rev Neurol. 2017;13(10):612\u201323.","journal-title":"Nat Rev Neurol"},{"issue":"7","key":"1245_CR33","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1001\/archneur.60.7.958","volume":"60","author":"H Fukumoto","year":"2003","unstructured":"Fukumoto H, Tennis M, Locascio JJ, Hyman BT, Growdon JH, Irizarry MC. Age but not diagnosis is the main predictor of plasma amyloid beta-protein levels. Arch Neurol. 2003;60(7):958\u201364.","journal-title":"Arch Neurol"},{"issue":"1","key":"1245_CR34","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.jalz.2012.12.006","volume":"10","author":"A Rembach","year":"2014","unstructured":"Rembach A, Faux NG, Watt AD, Pertile KK, Rumble RL, Trounson BO, et al. Changes in plasma amyloid beta in a longitudinal study of aging and Alzheimer\u2019s disease. Alzheimers Dement. 2014;10(1):53\u201361.","journal-title":"Alzheimers Dement"},{"issue":"10","key":"1245_CR35","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1136\/jnnp.2010.205757","volume":"81","author":"TT Sepp\u00e4l\u00e4","year":"2010","unstructured":"Sepp\u00e4l\u00e4 TT, Herukka SK, H\u00e4nninen T, Tervo S, Hallikainen M, Soininen H, et al. Plasma A\u03b242 and A\u03b240 as markers of cognitive change in follow-up: a prospective, longitudinal, population-based cohort study. J Neurol Neurosurg Psychiatry. 2010;81(10):1123\u20137.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2","key":"1245_CR36","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/alzrt162","volume":"5","author":"JB Toledo","year":"2013","unstructured":"Toledo JB, Shaw LM, Trojanowski JQ. Plasma amyloid beta measurements - a desired but elusive Alzheimer\u2019s disease biomarker. Alzheimers Res Ther. 2013;5(2):8.","journal-title":"Alzheimers Res Ther"},{"issue":"4","key":"1245_CR37","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.jalz.2012.01.001","volume":"8","author":"MJ Figurski","year":"2012","unstructured":"Figurski MJ, Walig\u00f3rska T, Toledo J, Vanderstichele H, Korecka M, Lee VM, et al. Improved protocol for measurement of plasma \u03b2-amyloid in longitudinal evaluation of Alzheimer\u2019s Disease Neuroimaging Initiative study patients. Alzheimers Dement. 2012;8(4):250\u201360.","journal-title":"Alzheimers Dement"},{"issue":"8","key":"1245_CR38","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1212\/WNL.52.8.1555","volume":"52","author":"F Hulstaert","year":"1999","unstructured":"Hulstaert F, Blennow K, Ivanoiu A, Schoonderwaldt HC, Riemenschneider M, Deyn PPD, et al. Improved discrimination of AD patients using \u03b2-amyloid(1\u201342) and tau levels in CSF. Neurology. 1999;52(8):1555\u201362.","journal-title":"Neurology"},{"key":"1245_CR39","first-page":"986310","volume":"2010","author":"M Bjerke","year":"2010","unstructured":"Bjerke M, Portelius E, Minthon L, Wallin A, Anckars\u00e4ter H, Anckars\u00e4ter R, et al. Confounding factors influencing amyloid beta concentration in cerebrospinal fluid. Int J Alzheimers Dis. 2010;2010:986310.","journal-title":"Int J Alzheimers Dis"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-023-01245-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-023-01245-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-023-01245-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,3]],"date-time":"2023-06-03T08:02:38Z","timestamp":1685779358000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-023-01245-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,3]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1245"],"URL":"https:\/\/doi.org\/10.1186\/s13195-023-01245-2","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,3]]},"assertion":[{"value":"25 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Vena punctures and lumbar punctures were performed after informed consent from the patients and controls. This study was approved by the Medical Ethics Committee Arnhem-Nijmegen (CAVIA; no. 2014-1401, BIONIC no. 2017-3810, controls no. 2016-3011) and Medical Ethics Committee of Leiden (AURORA; NL62670.058.17, FOCAS: NL63256.058.17, EDAN NL36994.058.11).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"102"}}